ClinicalTrials.gg
CompletedNCT01465763OCTAVEUpdated Jun 7, 2016Results posted

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

A Phase 3 interventional study of tofacitinib and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 178 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.

Enrollment
2nd of 14
614 · median 107
Started
2012
with 3 others
Phase 3
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
7 of 14
Pfizer

Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tofacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • tofacitinib
  • CP-690
  • 550
  • Moderate to severe ulcerative colitis
  • phase 3 clinical trial
  • Mayo score
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 18 years of age.
  • Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.
  • Subjects with moderately to severely active UC based on Mayo score criteria.
  • Subjects must have failed or be intolerant of at least one of the following treatments for UC:

    • (oral or intravenous).
    • Azathioprine or 6 mercaptopurine (6 MP).
    • Anti TNF-alpha therapy.

Exclusion criteria

Exclusion Criteria:

  • Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.
  • Subjects with disease limited to distal 15 cm.
  • Subjects without previous treatment for UC (ie, treatment naïve).
  • Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    tofacitinib 10 mg BID

    Drug: tofacitinib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 10 mg oral BID

    Also known as: CP-690,550

  • DrugPlacebo

    Plabebo oral BID

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Remission at Week 8

    Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Achieving Mucosal Healing at Week 8

    Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Week 8

  2. Percentage of Participants Achieving Clinical Response at Week 8

    Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Week 8

  3. Percentage of Participants With Endoscopic Remission at Week 8

    Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Week 8

  4. Percentage of Participants With Clinical Remission at Week 8

    Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Week 8

  5. Percentage of Participants With Symptomatic Remission at Week 8

    Symptomatic remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Week 8

  6. Percentage of Participants With Deep Remission at Week 8

    Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Week 8

  7. Partial Mayo Scores

    A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline, Weeks 2, 4, 8

  8. Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8

    Change in partial mayo scores at weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline, Weeks 2, 4, 8

  9. Change From Baseline in Total Mayo Scores at Week 8

    Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

    Time frame: Baseline, Week 8

07

Results

Posted Jun 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
Started47616122
Completed44515118
Not completed3114
Withdrew: Withdrawal by subject401
Withdrew: Insufficient clinical response1101
Withdrew: Adverse event901
Withdrew: Other200
Withdrew: Protocol violation411
Withdrew: Death100

Outcome measures

PrimaryPercentage of Participants With Remission at Week 8

Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Remission at Week 818.58.2
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0070 · Percent difference: 10.3 · 95% CI 4.3 to 16.3
SecondaryPercentage of Participants Achieving Mucosal Healing at Week 8

Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Mucosal Healing at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving Mucosal Healing at Week 831.315.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0005 · Percent difference: 15.7 · 95% CI 8.1 to 23.4
SecondaryPercentage of Participants Achieving Clinical Response at Week 8

Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving Clinical Response at Week 859.932.8
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = <0.0001 · Percent difference: 27.1 · 95% CI 17.7 to 36.5
SecondaryPercentage of Participants With Endoscopic Remission at Week 8

Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Endoscopic Remission at Week 86.71.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0345 · Percent difference: 5.1 · 95% CI 1.9 to 8.3
SecondaryPercentage of Participants With Clinical Remission at Week 8

Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Clinical Remission at Week 818.58.2
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0070 · Percent difference: 10.3 · 95% CI 4.3 to 16.3
SecondaryPercentage of Participants With Symptomatic Remission at Week 8

Symptomatic remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Symptomatic Remission at Week 811.85.7
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0601 · Percent difference: 6.0 · 95% CI 1.0 to 11.1
SecondaryPercentage of Participants With Deep Remission at Week 8

Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Deep Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Deep Remission at Week 86.50
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square test · p = 0.0043 · Percent difference: 6.5 · 95% CI 4.3 to 8.7
SecondaryPartial Mayo Scores

A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline, Weeks 2, 4, 8
Reported as:
Mean · units on a scale
Partial Mayo Scores
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Baseline: (n= 475, 121)6.3 ± 1.26.5 ± 1.2
At Week 2: (n= 465, 122)4.2 ± 2.25.2 ± 2.1
At Week 4: (n= 461, 118)3.5 ± 2.34.8 ± 2.4
At week 8: (n= 449, 119)3.2 ± 2.44.8 ± 2.5
SecondaryChange From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8

Change in partial mayo scores at weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline, Weeks 2, 4, 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Change at Week 2: (n= 464, 121)-2.1 ± 0.1-1.2 ± 0.2
Change at week 4: (n= 460, 117)-2.8 ± 0.1-1.6 ± 0.2
Change at week 8: (n= 448, 118)-3.1 ± 0.1-1.6 ± 0.2
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed-Effects Model · p = <0.0001 · Least square mean difference: -0.9 · 95% CI -1.3 to -0.5
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed-Effects Model · p = <0.0001 · Least square mean difference: -1.1 · 95% CI -1.5 to -0.7
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed-Effects Model · p = <0.0001 · Least square mean difference: -1.5 · 95% CI -1.9 to -1.1
SecondaryChange From Baseline in Total Mayo Scores at Week 8

Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Total Mayo Scores at Week 8
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Baseline (n= 472, 121)9.0 ± 1.49.1 ± 1.4
Change at Week 8 (n= 443, 117)-3.8 ± 2.8-1.9 ± 2.5
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = <0.0001 · Least square mean difference: -1.9 · 95% CI -2.5 to -1.4

Adverse events

Collected over Baseline up to Day 98. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 10 mg BID—16/476 (3.4%)148/476 (31.1%)
Tofacitinib 15 mg BID—0/16 (0%)12/16 (75%)
Placebo BID—5/122 (4.1%)38/122 (31.1%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
Colitis ulcerativeGastrointestinal disorders5/4760/162/122
Animal biteInjury, poisoning and procedural complications0/4760/161/122
Vulva cystReproductive system and breast disorders0/4760/161/122
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/4760/161/122
Acute coronary syndromeCardiac disorders1/4760/160/122
Intestinal perforationGastrointestinal disorders1/4760/160/122
MalaiseGeneral disorders1/4760/160/122
Drug hypersensitivityImmune system disorders1/4760/160/122
Anal abscessInfections and infestations1/4760/160/122
CellulitisInfections and infestations1/4760/160/122
Most frequent other events
Showing 10 of 25
Most frequent other events
EventTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
NasopharyngitisInfections and infestations34/4763/169/122
AcneSkin and subcutaneous tissue disorders10/4763/160/122
SinusitisInfections and infestations2/4762/161/122
HeadacheNervous system disorders37/4760/168/122
AnaemiaBlood and lymphatic system disorders11/4761/166/122
Colitis ulcerativeGastrointestinal disorders6/4761/163/122
FlatulenceGastrointestinal disorders2/4761/161/122
Gastrooesophageal reflux diseaseGastrointestinal disorders0/4761/160/122
NauseaGastrointestinal disorders15/4761/165/122
FatigueGeneral disorders10/4761/164/122

Baseline characteristics

The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.

Age, Customized
Age, Customized(participants)Tofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BIDTotal
18 to 44 Years2951172378
45 to 64 Years145439188
Greater Than or Equal to (>=) 65 Years3611148
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BIDTotal
Female199745251
Male277977363
08

Study locations

178 sites
  • Internal Medicine Center, LLC
    Mobile, Alabama 36608, United States
  • Springhill Memorial Hospital
    Mobile, Alabama 36608, United States
  • Investigational Drug Service Pharmacy
    La Jolla, California 92093, United States
  • UCSD Medical Center
    La Jolla, California 92093, United States
  • UCSD Medical Centre
    La Jolla, California 92093, United States
  • Cedars Sinai Medical Center - Thalians Bldg
    Los Angeles, California 90048, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Cedars Sinai Surgery Center
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • CRC Office - Cedars-Sinai Medical Center - Inflammatory Bowel Disease Center
    Los Angeles, California 90048, United States
  • Desert Advanced Imaging
    Palm Springs, California 92262, United States
  • Erik Palmer, DO
    Palm Springs, California 92262, United States
  • Homan A Zadeh, MD, MPH
    Palm Springs, California 92262, United States
  • Hope Square Surgical Center
    Rancho Mirage, California 92270, United States
  • Sharp Rees-Stealy Medical Group, Inc.
    San Diego, California 92101, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92101, United States
  • Sharp Rees-Stealy Medical Group,Inc
    San Diego, California 92123, United States
  • Endoscopy Center of Connecticut, LLC
    Guilford, Connecticut 06437, United States
  • Endoscopy Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Gastroenterology Center of Connecticut, PC
    Hamden, Connecticut 06518, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Florida Surgery Center
    Altamonte Springs, Florida 32701, United States
  • Center for Advanced Gastroenterology
    Maitland, Florida 32751, United States
  • MNH Surgical Center
    Maitland, Florida 32751, United States
  • Sand Lake Imaging
    Maitland, Florida 32751, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Orange Park Surgery Center
    Orange Park, Florida 32073, United States
  • Citrus Ambulatory Surgery Center
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Georgia Endoscopy Center (Colonoscopy only)
    Alpharetta, Georgia 30005, United States
  • GI Consultants (Colonoscopy only)
    Atlanta, Georgia 30342, United States
  • Emory Healthcare Heart Center (EKG)
    Johns Creek, Georgia 30097, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Icahn School of Medicine at Mount Sinai
    Marietta, Georgia 30067, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Johns Creek Diagnostic Center (X-Ray only)
    Suwanee, Georgia 30024, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • Saint Joseph Mercy Hospital - Inpatient Pharmacy (Pharmacy Only)
    Ann Arbor, Michigan 48106, United States
  • East Ann Arbor Health and Geriatrics Center - University of Michigan Health Systems
    Ann Arbor, Michigan 48109-2701, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109-5000, United States
  • Michigan Clinical Research Unit - Univeristy of Michigan Health System
    Ann Arbor, Michigan 48109-5872, United States
  • Medical Science Research Building 1 - University of Michigan Health Systems
    Ann Arbor, Michigan 48109, United States
  • Michigan Heart SJMH (Blood draws and ECGs only)
    Ypsilanti, Michigan 48106, United States
  • Huron Gastroenterology Associates / Center for Digestive Care
    Ypsilanti, Michigan 48197, United States
  • Saint Joseph Mercy Hospital Outpatient Laboratory (Blood draws only)
    Ypsilanti, Michigan 48197, United States
  • Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine - Division of Gastroenterology
    Saint Louis, Missouri 63110, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NYU Langone Nassau Gastroenterology Associates
    Great Neck, New York 11021, United States
  • The Private Practice of Simon Lichtiger, MD
    New York, New York 10028, United States
  • Mount Sinai Doctos Faculty Practice
    New York, New York 10029, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • CUMC Research Pharmacy
    New York, New York 10032, United States
  • Kornbluth, Legnani, George MD, PC
    New York, New York 10128, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Mentor Medical Campus
    Mentor, Ohio 44060, United States
  • The Endoscopy Center of Lake County
    Mentor, Ohio 44060, United States
  • Houston Hospital for Specialized Surgery
    Houston, Texas 77004, United States
  • Baylor College of Medicine (Baylor Medical Center)
    Houston, Texas 77030, United States
  • Baylor College of Medicine - Baylor Medical Center (Drug Storage)
    Houston, Texas 77030, United States
  • Gastroenterology Consultants, P.A.
    Houston, Texas 77034, United States
  • Alpine Medical Group
    Salt Lake City, Utah 84102, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • Wasatch Endoscopy Center
    Salt Lake City, Utah 84124, United States
  • RGL Medical Services (x-ray only)
    West Jordan, Utah 84084, United States
  • Wisconsin Center for Advanced Research - GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Eastern Health Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • AKH Wien, Universitaetsklinik fuer Innere Medizin III,
    Wien, 1090, Austria
  • UZ Leuven (University Hospital Leuven), Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hertiage Medical Research Clinic- University Of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • McMaster University Medical Center
    Hamilton, Ontario L8N 3Z5, Canada
  • Hamilton Health Sciences Corporation - McMaster University Medical Centre
    Hamilton, Ontario L8S 4K1, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Unidad de Gastroenterologia y Endoscopia Digestiva S.A. - UGASEND S.A.
    Barranquilla, Atlantico 00000, Colombia
  • General Hospital Zadar
    Zadar, 23 000, Croatia
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 500 12, Czech Republic
  • Institut klinicke a experimentalni mediciny
    Praha 4, 140 21, Czech Republic
  • Klinicke Centrum ISCARE I.V.F.
    Praha 7, 170 04, Czech Republic
  • Aalborg Hospital
    Aalborg, 9000, Denmark
  • Aarhus University Hospital
    Aarhus C, 8000, Denmark
  • ECG Unit of West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • West Tallinn Central Hospital Internal Diseases Clinic
    Tallinn, 10617, Estonia
  • X-Ray Department of West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • CHU de Nantes - Hotel Dieu
    Nantes, 44093, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • Hopital Rangueil
    Toulouse Cedex 9, 31059, France
  • Universitaetsmedizin Berlin, Charite Campus Virchow-Klinikum,
    Berlin, 13353, Germany
  • Universitaetsklinikum Halle (Saale)
    Halle, 06120, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Klinikum Luneburg/Abteilung Gastroenterologie
    Lüneburg, 21339, Germany
  • Szent Margit Korhaz III Belgyogyaszati Gasztroenterologiai Osztaly
    Budapest, 1032, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7624, Hungary

Showing the first 100 of 178 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084. PubMed 36342120 ↗
  • Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7. PubMed 36336750 ↗
  • Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96. doi: 10.1093/ibd/izac063. PubMed 35648151 ↗
  • Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 Jul;112(1):90-100. doi: 10.1002/cpt.2601. Epub 2022 Apr 27. PubMed 35380740 ↗
  • Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):51-61. doi: 10.1093/ibd/izac061. PubMed 35380664 ↗
  • Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1442-1453. doi: 10.1111/apt.16626. Epub 2021 Oct 6. PubMed 34614208 ↗
  • Farraye FA, Qazi T, Kotze PG, Moore GT, Mundayat R, Lawendy N, Sharma PP, Judd DT. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021 Aug;54(4):429-440. doi: 10.1111/apt.16439. Epub 2021 Jun 24. PubMed 34165201 ↗
  • Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka SR, Lichtenstein GR. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. doi: 10.1177/17562848211005708. eCollection 2021. PubMed 34035832 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 Mar;20(3):591-601.e8. doi: 10.1016/j.cgh.2021.02.043. Epub 2021 Mar 6. PubMed 33684552 ↗
  • Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 Mar;10(3):229-240. doi: 10.1002/cpdd.899. Epub 2021 Jan 29. PubMed 33513294 ↗
  • Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408. doi: 10.1093/ibd/izaa289. PubMed 33324993 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3. doi: 10.1016/j.cgh.2020.10.038. Epub 2020 Oct 27. PubMed 33127596 ↗
  • Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227. PubMed 32870265 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panes J. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. Inflamm Bowel Dis. 2021 Jun 15;27(7):983-993. doi: 10.1093/ibd/izaa193. PubMed 32794567 ↗
  • Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panes J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199. PubMed 32766762 ↗
  • Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. PubMed 31599001 ↗
  • Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8. PubMed 31077827 ↗
  • Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23. PubMed 30476584 ↗
  • Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10. PubMed 30012431 ↗
  • Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131. PubMed 29850873 ↗
  • Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018 Apr;16(2):233-245. doi: 10.5217/ir.2018.16.2.233. Epub 2018 Apr 30. Erratum In: Intest Res. 2018 Jul;16(3):499-501. doi: 10.5217/ir.2018.16.3.499. PubMed 29743836 ↗
  • Panes J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133. Erratum In: J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. PubMed 29028981 ↗
  • Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. PubMed 28467869 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2011
First posted
Nov 6, 2011
Start
Apr 2012
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jun 7, 2016
Last update
Jun 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01465763
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Apr 2012
Primary completion
May 2015
Completion
May 2015
Results posted
Jun 7, 2016
Last update
Jun 7, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion